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receptor-hormone interaction and its biolo-
gical significance.
PREDICTIVE VALUE OF ACID PHOS-
PHATASE. B. MORGAN. Department of
Chemical Pathology, University of Leeds.
There is increasing interest in the use of
clinical and biochemical data to assess the
probability that a patient has, or will develop,
a particular state. The complexity of these
techniques arises in part because they are
based on many variables measured in each
individual. Yet the aims of these techniques
are identical with the aims of making a single
measurement in each individual. It is these
aims which will be discussed here in relation
to a single variable, namely the serum acid
phosphatase activity, and a single clinical
condition, namely carcinoma of the prostate.
The ideal situation would have been as
follows: (1) Two groups were defined which
were comparable in all ways except that one
group had carcinoma of the prostate gland
(CA) and the other did not (N); (2) There was
a measurement (acid phosphatase) which was
simpler than the techniques used to separate
the initial groups and which had different
values in the groups CA and N; (3) There
was no overlap in the values of X in the
groups CA and N; (4) There was no other
condition which could be confused with
carcinoma of the prostate.
The real life situation is of course far
from this ideal. One fundamental difference
is that there is no complete separation of the
values of serum acid phosphatase (AP) in the
two groups (N and CA). Various changes in
technique have been suggested in order to
diminish this overlap of AP between the
groups. These changes are largely aimed at
improving organ specificity by the choice of
substrate and the addition of isoenzyme
inhibitors (Bodansky, Clin. Chem. 1972, 15,
43; Schwartz, Clin. Chemn., 1973, 19, 10).
While these attempts will no doubt
continue, it seems reasonable to conclude that
in this clinical situation, as in so many others,
a single measurement will not completely
discriminate between the groups and that
overlap of the results will remain.
What is so commonly done in practice is
to define a value (the upper limit of normal)
to assume that values above this will not
occur in healthy persons. The finding of a
high value then " indicates " the presence of
the disorder. This approach is an attempt to
make the situation like the ideal one with
complete discrimination.
However, this approach makes no use of
the information in the absolute value of the
measurement. Thus, the higher the value of
AP, the greater the probability of carcinoma
of the prostate. This probability is rarely
formally defined for a single variable al-
though it is now part of some complex
statistical analyses involving several variables
(Hartz, Clin. Chem., 1973, 19, 113). This
probability function must also take into
account the relative prevalence (probabilities)
of the disorders or states which are being
discriminated.
MULTIPARAMETRIC TESTS IN THE
STUDY OF GASTROINTESTINAL
NEOPLASMS. E. H. COOPER. Department
of Cancer Research, University of Leeds.
Several forms of cancer can be con-
veniently staged into a local growth, exten-
sion into local nodes, direct spread beyond
the organ of origin and distant metastases.
This sequence will have reached various
stages when the patient first presents and
after a variable time interval following the
excision of the primary tumour local recur-
rences or distant metastases may develop. A
team of laboratory workers and clinicians in
the Leeds Region and at the Chester Beatty
Institute, London has been examining the
way in which laboratory tests may aid the
diagnosis in gastrointestinal cancers, in
particular, colorectal cancer. This was
chosen partly in view of our participation in
the MRC trial on the evaluation of carcino-
embryonic antigen (CEA) and partly as the
evolution of colorectal cancer follows reason-
ably well-defined patterns. It soon became
apparent that apart from being able to
distinguish metastatic colorectal cancer in-
volving the liver from various types of
hepatitis and cirrhosis, CEA alone was
unable to discriminate the various stages of
evolution of colorectal cancer. As the liver
is the main site of distant metastasis the
contributions of serum enzyme, known to be
elevated in hepatic metastases, to a dis-
criminant function have been examined.
Gammaglutamyl transpeptidase, leucine
aminopeptidase and alkaline phosphataseSYMPOSIUM 191
have been estimated in parallel with the
CEA values in a wide spectrum of clinical
stages in the evolution of colorectal cancer.
A combination of yGT and CEA gave an
improvement in the discrimination of hepatic
metastases but this combination still appears
to lead to error in some patients with residual
diseases apparently confined to the pelvis.
The rise in serum yGT is a more sensitive
indicator of early metastases than AP or
LAP, but once the level of yGT was above
100 i.u./ml (normal = 13-9 ± 7-7 i.u./ml) the
rate of rise of AP and LAP parallel the
increase of yGT. The rates of increase of
these enzymes in advanced hepatic metastases
have a fairly uniform course. On the other
hand, the levels ofCEA are extremely variable
and there is no simple correlation between the
apparent extent of the metastases and the
CEA level.
Following individual patients by repeated
measurements after the excision of the
primary tumour has shown that the com-
bination of CEA and yGT can indicate
metastatic cancer several months before
clinical examination. Furthermore, the treat-
ment of advanced colorectal cancer with
chemotherapy produces a fall in the yGT and
the CEA values. Unfortunately, this com-
bination of CEA and yGT is reliable as an
indicator of hepatic metastases in only a few
types of tumours. It failed to identify many
forms of cancer that gave positive evidence
of metastases on liver scintiscans. This
preliminary experience has suggested that it
may be possible to set up other combinations
oftumour antigens and chemical indicators of
organ site involvement to help in the sur-
veillance of common forms of cancer. This
may be particularly appropriate when suitable
forms of chemotherapy are available to
warrant early treatment.
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THERE ARE a number of reasons for
desiring a set of predictive tests in cancer
therapy. Since the number of patients who
respond to radiation, hormonal and cancer
therapy represents only a fraction of those
treated, it follows that many patients are
treated unnecessarily. Many therapies that
are used to treat non-resectable cancer have
toxic side-effects, so that if we could identify
patients who would surely fail, and omit
useless therapy, radiation and chemothera-
peutic toxicity could be diminished. If we
could predict that a conventional therapy
would fail, this would facilitate early intro-
duction of a new and possibly effective
treatment. Since it usually takes 3 or more
weeks to observe whether treatment is
effective, the replacement of clinical observa-
tion with a predictive test could very possibly
save 3 or more weeks of treatment. Since
the median survial of patients with, for
example, acute myelogenous leukaemia, is
only 3 weeks, half of such patients could be
offered a new and possibly effective therapy
before death. Recently, combination chemo-
therapy has become very popular and toxici-
ties not previously induced are now tolerated
because of possible increased benefits. Yet,
empirical choice of agents may result in
addition of toxicity without increase of